ARCHIVES

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

This article is from The Cancer Letter archive.

Vol. 26 No. 25 | June 23, 2000

Download PDF Visit The Full Archive

Related Articles

Environmental Carcinogenesis Seen As Next Big Growth Field; NCA Hears Problems, Priorities

October 31, 1975

Hammer Blast GAO Report As ”Gobblygook”

June 12, 1987

Montana Drug Salesman Pleads Guilty to Selling Counterfeit Avastin

July 25, 2013

Cooperative Groups: Committee Formed To Implement Armitage Report Had A Rough Start

June 12, 1998

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

DCT Board Oks Recompetition Of Master Agreement For BRM Trials

February 4, 1983